How do Hemadid (ferrous sulfate), Globifer (heme iron polypeptide), and Fefol Spansule (ferrous fumarate) compare regarding elemental iron content, absorption, clinical efficacy, and side‑effect profile?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Comparison of Hemadid, Globifer, and Fefol Spansule

All three oral iron formulations—Hemadid (ferrous sulfate), Globifer (heme iron polypeptide), and Fefol Spansule (ferrous fumarate)—are similarly effective for treating iron deficiency anemia, but ferrous sulfate (Hemadid) should be your first-line choice due to its superior bioavailability, lowest cost, and equivalent efficacy to other formulations. 1

Elemental Iron Content

  • Hemadid (Ferrous Sulfate 200 mg): Contains 65 mg elemental iron per tablet
  • Fefol Spansule (Ferrous Fumarate): Typically contains 69-106 mg elemental iron depending on formulation (210-322 mg ferrous fumarate)
  • Globifer (Heme Iron Polypeptide): Variable content, typically lower doses (often 11-12 mg elemental iron per dose)

2

Absorption Profile

Ferrous sulfate demonstrates superior bioavailability compared to both ferrous fumarate and heme iron polypeptide. In preschool children, ferrous sulfate showed 7.9% absorption versus only 2.43% for ferrous fumarate—making sulfate more than 3 times better absorbed 3. Similarly, ferrous fumarate and ferrous sulfate showed equivalent absorption in iron-sufficient populations (RBV 86-106%), but sulfate consistently performed better in iron-deficient states 4.

Heme iron polypeptide (Globifer) theoretically bypasses hepcidin regulation through different absorption pathways, but clinical evidence is disappointing. A 2012 randomized controlled trial in peritoneal dialysis patients found no efficacy advantage for heme iron polypeptide over ferrous sulfate, with actually lower ferritin levels achieved 5. A 2024 meta-analysis showed heme iron may benefit children with anemia (MD 1.06 g/dL hemoglobin increase), but evidence quality was very low 6.

Critical absorption consideration: All ferrous salts trigger hepcidin elevation for 48 hours, blocking subsequent iron absorption. This means once-daily dosing is optimal—taking iron more frequently increases side effects without improving absorption 1.

Clinical Efficacy

No substantial evidence exists that any one oral iron product is better than another in effectiveness 1. The 2024 AGA guidelines explicitly state ferrous salts (sulfate, fumarate, gluconate) are reasonable first choices 1.

Expected hemoglobin response:

  • Should increase by ≥1 g/dL within 2 weeks of daily oral iron therapy
  • Failure to achieve this predicts subsequent treatment failure (sensitivity 90.1%, specificity 79.3%) 2
  • Recent data shows 50-100 mg elemental iron once daily produces adequate response 7

Ferrous sulfate 50 mg daily provided 1.44 mg absorbed iron versus only 0.54 mg for ferrous fumarate and 0.26 mg for reduced iron in fortified foods 3. This translates to meeting average daily iron requirements more effectively with sulfate.

Side Effect Profile

Gastrointestinal side effects are common with all oral iron formulations, occurring in approximately:

  • Constipation: 12%
  • Diarrhea: 8%
  • Nausea: 11%

1

Heme iron polypeptide (Globifer) demonstrates a 38% relative risk reduction in total side effects compared to non-heme iron (RR 0.62; 95% CI 0.40-0.96), though this evidence is very low quality 6. In pregnancy studies, ferrous bisglycinate showed the most favorable GI profile, while ferrous fumarate and ferrous sulfate had similar side effect rates 8.

Important caveat: Modified-release formulations like Fefol Spansule are specifically noted as "less suitable for prescribing" in British guidelines because iron is released beyond the duodenum/jejunum where absorption is optimal 2.

Higher doses increase side effects without improving absorption. In a 2025 study, twice-daily dosing (2×1) caused significantly more GI side effects than once-daily dosing, with similar final hemoglobin outcomes 7.

Practical Recommendations

Start with ferrous sulfate 200 mg (65 mg elemental iron) once daily on an empty stomach 1, 2. This provides the best balance of:

  • Proven bioavailability
  • Lowest cost (approximately £1-2.50 per 28 days vs £47.60 for alternatives)
  • Adequate efficacy
  • Manageable side effects

If GI intolerance occurs:

  1. Try taking with food (reduces absorption but improves tolerance)
  2. Consider alternate-day dosing (similar efficacy, fewer side effects)
  3. Switch to heme iron polypeptide only if conventional iron fails

Avoid Fefol Spansule (modified-release formulations) as first-line—they release iron in suboptimal absorption sites and are not recommended by guidelines 2.

Globifer (heme iron polypeptide) should be reserved for patients who fail or cannot tolerate conventional ferrous salts, given its 7-fold higher cost and lack of proven superiority 5. The theoretical absorption advantage does not translate to clinically meaningful outcomes in most populations.

Continue treatment for 3 months after hemoglobin normalization to replenish iron stores 2. Monitor hemoglobin every 4 weeks until normalized, then every 6 months to detect recurrence 2.

References

Research

A randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anaemia in peritoneal dialysis patients: HEMATOCRIT trial.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.